CHICAGO -- A first-in-class bispecific antibody targeting PD-1 and VEGF combined with chemotherapy significantly improved overall survival (OS) in patients with advanced squamous non-small cell lung cancer (NSCLC), according to the HARMONi-6 trial.
At a median follow-up of 21.4 months, the ivonescimab-chemotherapy combination in the first line reduced the risk of death by 34%, with a median OS of 27.9 months versus 23.7 months with tislelizumab (Tevimbra) plus chemotherapy (HR 0.66, 95% CI 0.50-0.87, P=0.0017), reported Shun Lu, MD, PhD, of the Shanghai Chest Hospital-Jiao Tong University School of Medicine, at a press briefing at the American Society of Clinical Oncology (ASCO) annual meeting. HARMONi-6 data also were published in The Lancet.
Estimated OS rates at 24 months were 64.7% in the ivonescimab group and 48.6% in the tislelizumab group, while the corresponding rates at 18 months were 70.5% and 61.3%, and at 12 months were 78.9% and 72.2%, respectively.
Lu and colleagues previously reported that HARMONi-6 met its primary outcome of progression-free survival (PFS), with ivonescimab-chemotherapy significantly improving median PFS by about 4 months versus tislelizumab-chemotherapy (11.1 months vs 6.9 months, HR 0.60, 95% CI 0.46–0.78, P<0.0001).
